No announcement yet.

The bacterial challenge: time to react - At least 25,000 die each year in Europe from multidrug-resistant bacteria

  • Filter
  • Time
  • Show
Clear All
new posts

  • The bacterial challenge: time to react - At least 25,000 die each year in Europe from multidrug-resistant bacteria

    Today a conference was opened in Uppsala, Sweden on anti-biotic resistance.


    An EMEA-publication from last year stated:

    - each year 25,000 die in Europe from multidrug-resistant bacteria.
    - costs at least EUR 1.5 billion each year.

    "Big Pharma" is not interested in developing new anti-biotics:

    - the aim is to use these as less as possible, no "blockbusters"
    - doctors and others tend to use a new medicine freely, so in a few years it doesn't work anymore.

    What is needed is a new businessmodel voor the pharmatheutic industry (read: more € and $ from the taxpayers) and strict rules / control for use of antibiotics.

    The bacterial challenge: time to react

    Executive summary

    Main findings:

    There is a gap between the burden of infections due to multidrug-resistant bacteria and the development of new
    antibiotics to tackle the problem.

    • Resistance to antibiotics is high among Gram-positive and Gram-negative bacteria that cause serious
    infections in humans and reaches 25% or more in several EU Member States.

    • Resistance is increasing in the EU among certain Gram-negative bacteria such as recently observed for
    Escherichia coli.

    • Each year, about 25 000 patients die in the EU from an infection with the selected multidrug-resistant

    • Infections due to these selected multidrug-resistant bacteria in the EU result in extra healthcare costs and
    productivity losses of at least EUR 1.5 billion each year.

    • Fifteen systemically administered antibacterial agents with a new mechanism of action or directed against a
    new bacterial target were identified as being under development with a potential to meet the challenge of
    multidrug resistance. Most of these were in early phases of development and were primarily developed
    against bacteria for which treatment options are already available.

    • There is a particular lack of new agents with new targets or mechanisms of action against multidrugresistant
    Gram-negative bacteria. Two such agents with new or possibly new targets and documented
    activity were identified, both in early phases of development.

    • A European and global strategy to address this gap is urgently needed.

    full report
    ?Addressing chronic disease is an issue of human rights ? that must be our call to arms"
    Richard Horton, Editor-in-Chief The Lancet

    ~~~~ Twitter:@GertvanderHoek ~~~ ~~~